ERC Einstein-Rockefeller-CUNY Center for AIDS research

ERC 爱因斯坦-洛克菲勒-纽约市立大学艾滋病研究中心

• 批准号: 10901420
• 负责人: HARRIS GOLDSTEIN
• 金额: $ 50.63万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10901420
• 关键词: AIDS prevention; Acceleration; Acquired Immunodeficiency Syndrome; Adherence; Affinity; Area; Award; Basic Science; Behavioral; Behavioral Research; Behavioral Sciences; Biological Markers; Cities; Clinical; Clinical Research; Clinical Sciences; Collaborations; Communities; Community Health; Country; County; Data; Development; Diagnosis; Eligibility Determination; Epidemic; Epidemiology; Failure; Financial Support; Funding; Future; Goals; Grant; HIV; HIV Infections; HIV diagnosis; HIV/AIDS; Health; Health system; Immunologic Adjuvants; Implant; Improve Access; Infection; Inflammatory; Infrastructure; Institution; Interdisciplinary Study; Investments; Knowledge; Lead; Leadership; Link; Location; Logistics; Medicine; Mental Health; Mental disorders; Mentors; Modality; National Institute of Mental Health; New York; New York City; Outcome; Paper; Pathogenesis; Patients; Persons; Play; Population; Prevention; Process; Productivity; Prophylactic treatment; Public Health; Public Health Schools; Publications; Publishing; Research; Research Personnel; Research Priority; Resources; Role; Services; Site; Strategic Planning; Technology; Translating; Translational Research; United States; United States National Institutes of Health; Universities; Vacuum; Viral; Viremia; Vision; antiretroviral therapy; base; behavioral study; catalyst; chimeric antigen receptor T cells; clinical center; college; economic disparity; epidemiology study; forging; implementation research; implementation science; implementation strategy; improved; innovation; member; neurochemistry; neutralizing antibody; next generation; novel; novel therapeutics; pandemic disease; pre-exposure prophylaxis; prevent; preventive intervention; programs; recruit; response; scale up; social disparities; success; synergism; therapy adherence; transmission process; uptake; working group

PROJECT SUMMARY ERC-CFAR: OVERALL As the HIV research community and public health systems implement the vision of Ending the HIV Epidemic (EHE), Centers for AIDS Research (CFAR) play a crucial role leading the trans-institutional and interdisciplinary research efforts needed to achieve this goal. We successfully filled a vacuum in New York City, a continuing epicenter of HIV infection previously lacking a CFAR, by creating the Einstein-Rockefeller-CUNY CFAR (ERC- CFAR). The ERC-CFAR brings together and synergizes the complementary expertise and resources of researchers from a strong basic and clinical research institution linked to a health system which treats >6,200 people with HIV, the Albert Einstein College of Medicine (Einstein); a globally pre-eminent basic science institution, Rockefeller University (Rockefeller); and a strong public health/implementation science institution, CUNY School of Public Health/Hunter College (CUNY), while establishing linkages to the NYC Department of Health and Mental Hygiene. Our vision is for the ERC-CFAR to serve as a catalyst to create innovation and contribute to EHE by breaking down institutional and disciplinary silos in our complementary basic, translational, clinical, epidemiologic, behavioral, and implementation research programs to accelerate development of new therapies, assess and overcome barriers to acceptability, uptake, and adherence, and prevent and cure HIV infections. The success of the ERC-CFAR Cores, SWGs, and infrastructure in amplifying the research productivity of our three institutions is illustrated by a >30% increase in our OAR FRB from ~$34 million in FY15 to ~$44.6 million in FY20 and the publication of >1,250 papers by ERC-CFAR investigators. Our ESIs obtained ~$20 million of external grant funding, including ~$7.5 million in NIH grants catalyzed by ~$500K we awarded for 14 pilot grants, a >16-fold return on investment. We also integrated the concerns of our community members, including PWH, into our strategic planning process by organizing a novel, highly trans-institutional and interdisciplinary Scientific Working Group (SWG), with greater than 30 members focused on our community’s priority research area, HIV and Mental Health. In this renewal, we propose to build on our accomplishments to further catalyze research to end the epidemic through these Specific Aims: 1) To assemble transinstitutional, interdisciplinary, community-inclusive ERC-CFAR research teams to develop and implement new strategies to reduce HIV transmission, improve prevention and treatment, promote sustained viral suppression, and eradicate HIV reservoirs; 2) To increase the impact of our research through the cutting-edge services of our Biomarkers and Advanced Technologies Core, Behavioral and Implementation Science Core, and Clinical and Translational Science Core; 3) To mentor the next generation of HIV investigators, recruit established non-HIV investigators into HIV research, and forge new collaborations across Einstein, Rockefeller, and CUNY, other NIH-funded centers, regional academic centers, our public health departments, and community partners to support an innovative EHE agenda through the Developmental Core and current HIV & Mental Health and future SWGs.

项目总结 ERC-CFAR：总体 随着艾滋病毒研究界和公共卫生系统执行结束艾滋病毒流行的愿景 (EHE)、艾滋病研究中心(CFAR)在领导跨机构和跨学科的 实现这一目标所需的研究努力。我们成功地填补了纽约市的真空，继续 艾滋病毒感染的震中以前没有CFAR，通过创建爱因斯坦-洛克菲勒-CUNY CFAR(ERC- CFAR)。ERC-CFAR汇集并协同了以下方面的互补专业知识和资源 来自强大的基础和临床研究机构的研究人员与治疗&>6,200； 艾伯特·爱因斯坦医学院(爱因斯坦)；全球卓越的基础科学 洛克菲勒大学(洛克菲勒)；一个强大的公共卫生/实施科学机构， 纽约州立大学公共卫生学院/亨特学院(CUNY)，同时与纽约市公共卫生学院 健康与精神卫生。我们的愿景是让ERC-CFAR成为创造创新和 通过打破我们互补的基础、翻译、 临床、流行病学、行为和实施研究计划，以加速开发新的 治疗，评估和克服接受、吸收和坚持方面的障碍，预防和治愈艾滋病毒 感染。ERC-CFAR核心、SWG和基础设施在扩大研究方面的成功 我们的Oar FRB从2015财年的约3400万美元增长了30%，这说明了我们三家机构的生产率 到20财年达到4460万美元，以及ERC-CFAR调查人员发表1,250篇论文。我们的电子邮件已收到 ~2000万美元的外部赠款资金，包括由我们授予的~50万美元催化的~750万美元的NIH赠款 对于14笔试点赠款，投资回报率为16倍。我们还整合了社区成员的关切， 包括威尔斯亲王，通过组织一个新颖的、高度跨机构的和 跨学科科学工作组(SWG)，有30多名成员，专注于我们社区的 优先研究领域，艾滋病毒和精神健康。在这次更新中，我们建议在我们成就的基础上再接再厉， 通过这些具体目标进一步催化研究，以结束这一流行病：1)集合跨机构， 跨学科、社区包容的ERC-CFAR研究团队制定和实施新战略，以 减少艾滋病毒传播，改进预防和治疗，促进病毒持续抑制，根除 HIV蓄水池；2)通过我们的生物标志物的尖端服务增加我们研究的影响 和高级技术核心、行为和实施科学核心以及临床和翻译 科学核心；3)指导下一代艾滋病毒调查员，招募老牌非艾滋病毒调查员 投入艾滋病毒研究，并在爱因斯坦、洛克菲勒和纽约州立大学以及其他由NIH资助的机构之间建立新的合作 中心、地区学术中心、我们的公共卫生部门和社区合作伙伴 通过发展核心和当前的艾滋病毒与心理健康和未来特别关注群体创新的EHE议程。

项目成果

Meeting Our Patients "Where They Are": Video-Group Smoking Cessation for People Living With HIV.

• DOI: 10.1016/j.jana.2017.09.007
• 发表时间: 2018-03
• 期刊: The Journal of the Association of Nurses in AIDS Care : JANAC
• 作者: Marhefka SL;Turner D;Lockhart E;Rivara A;Wang W;Shuter J
• 通讯作者: Shuter J

Costing analysis of an SMS-based intervention to promote HIV self-testing amongst truckers and sex workers in Kenya.

• DOI: 10.1371/journal.pone.0197305
• 发表时间: 2018
• 期刊: PloS one
• 影响因子: 3.7
• 作者: George G;Chetty T;Strauss M;Inoti S;Kinyanjui S;Mwai E;Romo ML;Oruko F;Odhiambo JO;Nyaga E;Mantell JE;Govender K;Kelvin EA
• 通讯作者: Kelvin EA

Prevalence of and Factors Associated with the Use of HIV Serosorting and Other Biomedical Prevention Strategies Among Men Who Have Sex with Men in a US Nationwide Survey.

• DOI: 10.1007/s10461-018-2084-7
• 发表时间: 2018-08
• 期刊: AIDS and behavior
• 影响因子: 4.4
• 作者: Grov C;Jonathan Rendina H;Patel VV;Kelvin E;Anastos K;Parsons JT
• 通讯作者: Parsons JT

ASSOCIATION OF SOCIAL NEEDS WITH UNCONTROLLED VIREMIA IN PEOPLE WITH HIV.

艾滋病毒患者的社会需求与不受控制的病毒血症的关联。

• DOI: 10.1007/s10461-022-03703-8
• 发表时间: 2022-11
• 期刊: AIDS and behavior
• 影响因子: 4.4

Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?

• DOI: 10.1093/cid/ciac751
• 发表时间: 2022-11-21
• 期刊: CLINICAL INFECTIOUS DISEASES
• 影响因子: 11.8
• 作者: Caskey, Marina;Kuritzkes, Daniel R.
• 通讯作者: Kuritzkes, Daniel R.